Clearmind Medicine Inc. announced notice of publication by the China National Intellectual Property Administration, referring to the Company's proprietary non hallucinogenic compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of depression. Preclinical studies have demonstrated MEAI's potential to enhance mood regulation and reduce anhedonia, offering a differentiated therapeutic approach for patients who do not respond to conventional antidepressants. This patent application further reinforces Clearmind's robust IP portfolio, which now includes protections across multiple jurisdictions for MEAI's applications in various mental health and addiction disorders.